Sanofi France confirms atorvastatin accord with Pfizer
This article was originally published in Scrip
Sanofi France has confirmed to Scrip that it has signed a licensing deal with Pfizer to manufacture the cholesterol lowering blockbuster atorvastatin in France. The company further confirmed that it will not launch Tahor, the name for its version of the drug, until after the Lipitor patent has expired fully in France on 7 May 2012. While the US patent for Lipitor expires in November 2011, Pfizer secured a six month extension to its European exclusivity through a paediatric supplementary protection certificate.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.